These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 37994013)

  • 1. A 47-Year-Old Man with Hyperphosphatemia Due to Chronic Renal Failure Treated with Lanthanum Carbonate Tablets Presenting Acutely with Partial Large Bowel Obstruction.
    Zhou Q; Yu M; Chang X; Shang S; Li M; Xu W
    Am J Case Rep; 2023 Nov; 24():e942113. PubMed ID: 37994013
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Treating Hyperphosphatemia With Lanthanum Carbonate vs Calcium Carbonate on Cardiovascular Events in Patients With Chronic Kidney Disease Undergoing Hemodialysis: The LANDMARK Randomized Clinical Trial.
    Ogata H; Fukagawa M; Hirakata H; Kagimura T; Fukushima M; Akizawa T;
    JAMA; 2021 May; 325(19):1946-1954. PubMed ID: 34003226
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Beam-hardening artifacts on computed tomography images caused by lanthanum carbonate hydrate in a patient on dialysis.
    Hayashi H; Machida M; Sekine T; Yamaguchi H; Kiriyama T; Kumita S
    Jpn J Radiol; 2010 May; 28(4):322-4. PubMed ID: 20512553
    [TBL] [Abstract][Full Text] [Related]  

  • 4. One year efficacy and safety of lanthanum carbonate for hyperphosphatemia in Japanese chronic kidney disease patients undergoing hemodialysis.
    Shigematsu T;
    Ther Apher Dial; 2010 Feb; 14(1):12-9. PubMed ID: 20438515
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Lanthanum carbonate in clinical practice].
    Torregrosa Prats V
    Nefrologia; 2008; 28 Suppl 5():11-4. PubMed ID: 18847414
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lanthanum carbonate effectively controls serum phosphate without affecting serum calcium levels in patients undergoing hemodialysis.
    Shigematsu T;
    Ther Apher Dial; 2008 Feb; 12(1):55-61. PubMed ID: 18257813
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multicenter prospective randomized, double-blind comparative study between lanthanum carbonate and calcium carbonate as phosphate binders in Japanese hemodialysis patients with hyperphosphatemia.
    Shigematsu T;
    Clin Nephrol; 2008 Nov; 70(5):404-10. PubMed ID: 19000540
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Characteristics of Seven Patients with Lanthanum Phosphate Deposition in the Stomach.
    Murakami N; Yoshioka M; Iwamuro M; Nasu J; Nose S; Shiode J; Okada H; Yamamoto K
    Intern Med; 2017 Aug; 56(16):2089-2095. PubMed ID: 28781325
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Higher strength lanthanum carbonate provides serum phosphorus control with a low tablet burden and is preferred by patients and physicians: a multicenter study.
    Mehrotra R; Martin KJ; Fishbane S; Sprague SM; Zeig S; Anger M;
    Clin J Am Soc Nephrol; 2008 Sep; 3(5):1437-45. PubMed ID: 18579668
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of lanthanum carbonate on phosphate control in continuous ambulatory peritoneal dialysis patients in Korea: a randomized prospective study.
    Lee YK; Choi HY; Shin SK; Lee HY
    Clin Nephrol; 2013 Feb; 79(2):136-42. PubMed ID: 23211335
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Questionnaire survey and serum phosphorus levels in maintenance hemodialysis patients switching lanthanum carbonate formulation from chewable tablets to granules.
    Mukai I; Yoshizawa T; Kumagai J; Takahashi N; Tsuchiya S
    Ther Apher Dial; 2014 Jun; 18 Suppl 1():28-33. PubMed ID: 24953764
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lanthanum carbonate versus placebo for management of hyperphosphatemia in patients undergoing peritoneal dialysis: a subgroup analysis of a phase 2 randomized controlled study of dialysis patients.
    Hutchison AJ; Gill M; Copley JB; Poole L; Wilson RJ
    BMC Nephrol; 2013 Feb; 14():40. PubMed ID: 23418668
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Intestinal pseudo-occlusion due to lanthanum carbonate].
    Pobes Martínez de Salinas A; Blanco Rodríguez I; Quiñones Ortiz L; Suárez Laurés A
    Nefrologia; 2010; 30(3):376. PubMed ID: 20514115
    [No Abstract]   [Full Text] [Related]  

  • 14. Cognitive function in Stage 5 chronic kidney disease patients on hemodialysis: no adverse effects of lanthanum carbonate compared with standard phosphate-binder therapy.
    Altmann P; Barnett ME; Finn WF;
    Kidney Int; 2007 Feb; 71(3):252-9. PubMed ID: 17035945
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Deposits of lanthanum in the gastric mucosa of a patient with chronic kidney disease].
    António da Conceiçao A; Chiva Robles MT; Porres Cubero JC; Saus Sarrias C; Castellano Megías VM
    Rev Esp Patol; 2019; 52(2):112-116. PubMed ID: 30902374
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lanthanum carbonate is an effective hypophosphatemic agent for hemodialysis patients intolerant of other phosphate binders.
    Chan WL; Rounsley K; Chapman E; Collings K; Dale C; De Waal S; Patel V; Tanner J; Turner E; Moore J; Borrows R
    J Ren Nutr; 2010 Jul; 20(4):270-7. PubMed ID: 20362463
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical usefulness of lanthanum carbonate for serum phosphate control in difficult patients.
    Almirall J; Betancourt L; Esteve V; Valenzuela MP; López T; Ruiz A; Martínez-Ocaña JC; Calvet X
    Int Urol Nephrol; 2012 Feb; 44(1):231-6. PubMed ID: 21069570
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy evaluation of lanthanum carbonate for hyperphosphatemia in end-stage renal disease patients.
    Shigematsu T; Ohya M; Negi S; Masumoto AR; Nakashima YM; Iwatani Y; Moribata MK; Yamanaka S; Tatsuta K; Mima T
    Contrib Nephrol; 2015; 185():42-55. PubMed ID: 26023014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Review of the diagnosis of gastrointestinal lanthanum deposition.
    Iwamuro M; Urata H; Tanaka T; Okada H
    World J Gastroenterol; 2020 Apr; 26(13):1439-1449. PubMed ID: 32308345
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized, double-blind, placebo-controlled, dose-titration, phase III study assessing the efficacy and tolerability of lanthanum carbonate: a new phosphate binder for the treatment of hyperphosphatemia.
    Joy MS; Finn WF;
    Am J Kidney Dis; 2003 Jul; 42(1):96-107. PubMed ID: 12830461
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.